深圳市美好创亿医疗科技股份有限公司 （五）检查公司各分支机构、子公司的经营情况。 总经理轮值制度 2025 年 4 月 深圳市美好创亿医疗科技股份有限公司 总经理轮值制度 第一条 为了适应深圳市美好创亿医疗科技股份有限公司（以下简称"公司"） 经营发展需要，构建完善科学的管理机制，推动公司战略有效执行，培养高素质 管理团队，促进公司健康可持续发展，公司决定实行总经理轮值制度。现根据《中 华人民共和国公司法》等法律法规和《深圳市美好创亿医疗科技股份有限公司章 程》（以下简称"《公司章程》"）以及《深圳市美好创亿医疗科技股份有限公 司总经理工作细则》（以下简称"《总经理工作细则》"）的有关规定，特制定 本制度。 第二条 公司实行董事会领导下的总经理（轮值）负责制，公司的轮值总经 理候选人需满足《公司法》《证券法》等法律法规以及《公司章程》《总经理工 作细则》等规定中关于总经理的任职要求。 第三条 本轮值总经理的职责： （一）轮值总经理根据《公司章程》《总经理工作细则》及董事会授权行使 相应职权，履行相应职责； （二）按照《总经理工作细则》的规定或者董事会、监事会的要求向董事会、 监事会进行汇报； （三）总揽公司发 ...

公司在任独立董事吴学斌先生、王建新先生及梁永晔先生均能够胜任独立董 事的职责要求，其均未在公司担任除独立董事以外的任何职务，也未在公司主要 股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况。因此，公司 全体在任独立董事均符合《上市公司独立董事管理办法》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范性 文件及《公司章程》中关于独立董事独立性的相关要求。 深圳市美好创亿医疗科技股份有限公司董事会 关于独立董事 2024 年度保持独立性情况的专项意见 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）董事会根据《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关规定的要求，并结合独立董事出具的《独立董 事关于 2024 年度独立性的自查报告》，就公司在任独立董事的独立性情况进行评 估并出具如下专项意见： 深圳市美好创亿医疗科技股份有限公司董事会 2025 年 4 月 18 日 1 专此意见。 ...

深圳市美好创亿医疗科技股份有限公司 章 程 2025 年 4 月 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 9 | | 第二节 | 股东大会的一般规定 11 | | 第三节 | 股东大会的召集 16 | | 第四节 | 股东大会的提案与通知 18 | | 第五节 | 股东大会的召开 19 | | 第六节 | 股东大会的表决和决议 23 | | 第五章 | 董事会 28 | | 第一节 | 董事 28 | | 第二节 | 董事会 32 | | 第六章 | 总经理及其他高级管理人员 37 | | 第七章 | 监事会 39 | | 第一节 | 监事 39 | | 第二节 | 监事会 40 | | 第八章 | 财务会计制度、利润分配和审计 42 | | 第一节 | 财务会计制度 42 | | 第二节 | 内部审计 45 | | 第三节 | 会计师事务所的 ...

建立和完善激励约束机制，确保本激励计划的顺利实施，促进公司发展战略 和经营目标的实现。 二、考核原则 考核评价工作严格按照本办法执行，坚持公正、公开、公平的原则，与激励 对象的工作绩效紧密挂钩，达到良好的激励和约束效果。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）为持续推进长 期激励机制的建设，吸引和留住优秀人才，有效结合股东利益、公司利益和员工 利益，遵循收益与贡献对等的原则，推出 2025 年限制性股票激励计划（以下简 称"本激励计划"）。 为保证本激励计划的顺利实施，公司根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务办理》 《公司章程》等有关规定，结合实际情况，制定《2025 年限制性股票激励计划 考核管理办法》（以下简称"本办法"）。 深圳市美好创亿医疗科技股份有限公司 一、考核目的 2025 年限制性股票激励计划考核管理办法 三、考核对象 本办法适用于本激励计划确定的激励对象，可包括公司董事、高级管理人员 以及公司（含子公司）其他核心员工，不包括公司独立董事 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.9000 | 0.7700 | 16.88 | 1.0800 | | 每股净资产（元） | 0 | 7.83 | -100 | 7.43 | | 每股公积金(元) | 3.99 | 3.93 | 1.53 | 3.93 | | 每股未分配利润(元) | 3.43 | 2.72 | 26.1 | 2.33 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 15.94 | 13.38 | 19.13 | 14.15 | | 净利润(亿元) | 3.64 | 3.13 | 16.29 | 4.02 | | 净资产收益率(%) | 10.96 | 10.10 | 8.51 | 21.16 | 前十大流通股东累计持有： 4013.32万股，累计占流通股比： 35.79%，较上期变化： -557.58万股。 | 名称 | 持有数量(万股) | 占总股本比 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,594,208,109.70, representing a 19.19% increase compared to ¥1,337,586,673.34 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥363,776,477.42, up 16.11% from ¥313,300,575.05 in 2023[22]. - The cash flow from operating activities for 2024 was ¥448,205,947.91, reflecting a 27.80% increase from ¥350,716,361.92 in 2023[22]. - The total assets at the end of 2024 amounted to ¥3,921,612,493.46, an 11.31% increase from ¥3,523,270,170.04 at the end of 2023[22]. - The basic earnings per share for 2024 was ¥0.90, a 16.88% increase from ¥0.77 in 2023[22]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥350,302,224.41, a 20.37% increase from ¥291,017,312.35 in 2023[22]. - The weighted average return on equity for 2024 was 10.96%, up from 10.10% in 2023[22]. - The company's total revenue for 2024 reached ¥1,594,208,109.70, representing a year-on-year increase of 19.19% compared to ¥1,337,586,673.34 in 2023[97]. - Medical segment revenue accounted for 84.23% of total revenue, amounting to ¥1,342,834,250.22, with a year-on-year growth of 24.53%[97]. Market Strategy and Expansion - The company has a comprehensive strategy for market expansion and product development, although specific figures are not detailed in the provided content[4]. - The company expects continued growth in revenue and profit margins driven by new product launches and market expansion strategies[22]. - The company has plans for further market expansion and potential acquisitions to enhance its competitive position[22]. - The company is focusing on diversified business layouts in high-potential markets such as blood glucose management and cardiovascular devices, aiming to create additional value growth curves[83]. - The company aims to enhance its global competitiveness by establishing overseas production bases, with the first and second phases of the Malaysian production base successfully launched[141]. - The company plans to enhance its overseas NPI development capabilities, including precision mold design and automation system development, to meet global customer delivery needs[150]. Research and Development - The company is committed to continuous investment in R&D to enhance its core technological advantages in various medical device segments[70]. - The company's R&D expenses reached 141 million yuan, an increase of 16.75% year-on-year, accounting for 8.82% of total revenue[73]. - The company holds 263 authorized patents, including 38 invention patents, and has 22 medical device registration certificates[73]. - The company has established a modular technology platform that enhances the efficiency of shared technology reuse and strengthens its capabilities in specialized fields[72]. - The company has developed advanced mold design solutions to enhance product quality and efficiency, addressing issues like air bubbles and overflow in traditional processes[110]. Quality Management and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management team[3]. - The company adheres to international standards such as ISO13485 and GMP for quality management in its manufacturing processes[17]. - The company has established a robust quality management system compliant with ISO13485 standards across its production bases in Huizhou, Shenzhen, and Penang, Malaysia[67]. - The medical device industry faces high quality and regulatory standards, with strict compliance required throughout the product lifecycle from development to post-market services[48]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to operational plans and future strategies[4]. - The company has undergone a board meeting where all directors were present to review the annual report[4]. - The company has implemented a risk management system for foreign exchange hedging, including measures to control operational, credit, and legal risks[132]. - The company faces risks related to the use of raised funds, including potential project delays and market acceptance issues[156]. Corporate Governance - The company emphasizes transparency and investor relations, adhering to strict information disclosure regulations[172]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[173]. - The company has established an independent financial department with a complete financial accounting system, ensuring no shared bank accounts with controlling shareholders[176]. - The company has a complete and independent business system, with no competition or unfair transactions with controlling shareholders[178]. Shareholder Engagement - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[168]. - The annual shareholders' meeting for 2023 had a participation rate of 77.34% and was held on May 9, 2024[180]. - The company held its first temporary shareholders' meeting in 2024 with a participation rate of 75.22% on February 27, 2024[180]. Product Development and Innovation - The company is developing a high-performance medical ventilator fan, achieving a maximum pressure of 60cmH2O and a maximum flow of 250L/min[106]. - The company has achieved mass production of a switchable nitric oxide detector, improving its respiratory product line and overall competitiveness[107]. - The company has developed a disposable endoscopic ultrasound biopsy needle, targeting the high-value consumables market currently dominated by foreign brands[107]. - The company aims to leverage its years of experience in silicone product manufacturing to develop high-value consumable products[107]. Financial Management - The company has implemented a comprehensive procurement management system to ensure quality control and supplier management[66]. - The company reported a significant increase in asset impairment losses of ¥-13,816,908.61, which accounted for -3.37% of total profit, mainly due to inventory impairment provisions[121]. - The company's cash and cash equivalents represented 31.93% of total assets at the end of 2024, down from 48.48% at the beginning of the year, a decrease of 16.55%[122]. Talent Management - The company aims to attract international talent and establish a stable, sustainable talent pipeline to support its global expansion strategy[151]. - The number of R&D personnel increased to 465 in 2024, up by 8.14% from 430 in 2023, with a proportion of 19.06%[115]. - The R&D personnel aged 30-40 increased by 31.25% to 210 in 2024, indicating a shift in the age structure of the R&D team[115].

证券代码：301363 证券简称：美好医疗 公告编号：2025-007 深圳市美好创亿医疗科技股份有限公司 关于开立募集资金专项账户 并签订募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）、深圳证券交易 所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上市 的通知》（深证上〔2022〕986 号）同意，深圳市美好创亿医疗科技股份有限公 司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 4,427 万股， 发行价格为 30.66 元/股，募集资金总额 1,357,318,200.00 元，扣除发行费用人民 币 132,529,143.83 元后，募集资金净额为 1,224,789,056.17 元。天健会计师事务 所（特殊普通合伙）已对公司首次公开发行股票的资金到位情况进行了审验，并 于 2022 年 9 月 30 日出具了《验资报告》（天健验〔202 ...

Company Overview - Meihao Medical closed at 22.73 yuan, down 19.25%, with a rolling PE ratio of 34.10 times and a total market value of 9.243 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 43.33 times and a median of 27.80 times, placing Meihao Medical at the 79th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Meihao Medical was 9,334, an increase of 687 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home ventilator components, cochlear implant components, other medical product components, precision molds, automation equipment, and components for home and consumer electronics [1] - The company has been recognized multiple times as a "Best Supplier" by Client A and awarded "Most Valuable Service and Excellent Partner" by Client B for five consecutive years [1] Financial Performance - In the latest quarterly report for Q3 2024, Meihao Medical achieved a revenue of 1.157 billion yuan, representing a year-on-year increase of 10.86% [1] - The net profit for the same period was 258 million yuan, showing a year-on-year decrease of 14.07% [1] - The sales gross margin stood at 41.78% [1]

4月1日，美好医疗今日收盘29.8元，上涨2.05%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到44.70倍，创27天以来新低，总市值121.18亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)84美好医疗44.7038.683.58121.18亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 来源：金融界 ...

最新一期业绩显示，2024年三季报，公司实现营业收入11.57亿元，同比10.86%；净利润2.58亿元，同 比-14.07%，销售毛利率41.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)83美好医疗43.1737.363.45117.04亿行业平均 45.2249.254.85107.95亿行业中值32.5731.042.4948.28亿1硕世生物-1928.41-1928.411.2139.84亿2诺唯 赞-570.10-570.102.4696.93亿3博晖创新-299.11-184.163.3045.91亿4康泰医学-292.1334.272.9856.81亿5华 大基因-217.12237.502.25220.63亿6奥精医疗-119.63-119.631.5221.67亿7睿昂基因-82.87-82.871.2911.99亿 8华大智造-55.62-55.624.17333.25亿9中红医疗-54.23-36.890.8648.28亿10热景生物-49.79-49.792.7489.25亿 11天智航-46.17-46.174.8256.85亿 资金流向方面，3月28日，美好医 ...